HOME >> MEDICINE >> NEWS
Immunex Advances CD40 Ligand To Phase II Clinical Trial In People With Metastatic Kidney Cancer

CD40L Moved Forward Based On Outcomes Of Multi-Dose Safety Trial

SEATTLE - Immunex Corporation (Nasdaq: IMNX) announced today that it has launched a Phase II trial of the investigational agent CD40 Ligand (CD40L) in the most common form of kidney cancer, renal cell carcinoma. The company is continuing the development of CD40L based on results of a multi-dose Phase I trial of the drug in advanced cancer patients.

The Phase I study, which evaluated escalating doses of CD40L in patients with recurrent solid tumors and lymphoma, has been completed and the objectives of the study were met. The results of this multi-dose study will be presented at a future medical meeting. Several pre-clinical studies on the anti-tumor effect of CD40L will be presented next week at the 35th Annual Meeting of the American Society of Clinical Oncology (ASCO). In these studies, conducted in both mice and fresh human tumor samples, CD40L inhibited tumor growth in multiple solid tumor types, such as breast, lung, ovarian and colon.

"Based on the results of these safety trials, Immunex is moving forward with a Phase II trial of CD40L in metastatic renal cell carcinoma," said Ann Hayes, M.D., senior vice president, medical development, Immunex. "Patients with this disease currently have limited treatment options. Treatment with CD40L represents a novel approach to treating cancer, by potentially having a direct effect on tumor cells and by stimulating the immune system to recognize and seek out cancer cells for destruction."

The study, being conducted in three cancer treatment centers across the United States, will evaluate the safety and efficacy of the drug in metastatic renal cell carcinoma.

Approximately 30,000 new cases of kidney cancer will be diagnosed this year in the United States and about 11,900 people will die from this disease. It is the 8th most common cancer in men and the 10th most common in women. Ren
'"/>

Contact: Lisa Crisera
criseral@immunex.com
206-389-4346
Immunex Corporation
14-May-1999


Page: 1 2

Related medicine news :

1. Immunex Files Supplemental NDA for NOVANTRONE
2. Immunexs TRAIL Molecule Shows Potential As Anti-Tumor Agent
3. Advances in Uterine Leiomyoma Research: 2nd NIH International Congress
4. Advances in plasma physics at Annual APS Meeting
5. Advances in plasma physics at Annual APS Meeting
6. Advances in understanding brain circuits responsible for tics in Tourettes shed light on disorder
7. Advances in Skeletal Anabolic Agents for the Treatment of Osteoporosis: A scientific meeting
8. Advances emerging in hepatitis management
9. Advances in prevention and treatment research hold promise for pipeline
10. Advances in MRI imaging may lead to new standards for faster diagnosis of multiple sclerosis
11. Peanut Allergy: Major Advances in Treatment and Education

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/3/2020)... Fla. (PRWEB) , ... September 03, 2020 , ... ... announced it is sponsoring the American Foundation for Suicide Prevention’s (AFSP) annual signature ... a million people across hundreds of U.S. cities to raise awareness of suicide ...
(Date:9/3/2020)... ... September 03, 2020 , ... The American Medical Spa ... April 7, to Saturday, April 10, 2021, at Wynn Las Vegas. The event ... national trade show for non-invasive medical aesthetic practices that brings together owners, physicians, ...
(Date:9/3/2020)... ... September 03, 2020 , ... International ... Technologies WALI wireless parking lot controller. This advanced LED wireless dimming controller, along ... trespass, and protecting the night sky against light pollution. Leo Smith, the Northeast ...
(Date:9/1/2020)... GLENDALE, Calif. (PRWEB) , ... September 01, 2020 ... ... opened a new practice in Glendale. While the office will be ... procedures as breast augmentation, tummy tucks, buttock augmentation (Brazilian butt lift), as well ...
(Date:9/1/2020)... ... 2020 , ... Feeding Matters , the first organization in the world ... is pleased to announce that the U.S. Centers for Disease Control and Prevention (CDC) ... next edition of the U.S. International Classification of Diseases (ICD ) on October ...
Breaking Medicine News(10 mins):
(Date:8/28/2020)... ... August 28, 2020 , ... ... beauty, bringing a unique perspective and approach. Armed with her qualifications from Ross ... to share her knowledge of the human body with the nation and world. ...
(Date:8/27/2020)... ... August 27, 2020 , ... Trella Health, ... a leading provider of cloud CRM, marketing automation, and contact center solutions for ... involve the integration of Trella’s performance intelligence data and insights into Enquire’s CRM ...
(Date:8/26/2020)... Mo. (PRWEB) , ... August ... ... a member of Eurofins BioPharma Services, Laboratory Testing division, expands its technology ... existing suite of Flow Cytometry platforms available. With industry-leading biomarker solutions, complemented ...
Breaking Medicine Technology:
Cached News: